Our findings establish lactylation as a critical determinant of neuroblastoma progression and prognosis. The seven-gene lactylation-related prognostic model provides a novel tool for patient stratification and therapeutic decision-making. Additionally, KLHL32 represents a promising target for enhancing immunotherapy efficacy by modulating metabolic and immune pathways, offering new opportunities for precision treatment in high-risk neuroblastoma patients.
Zhu et al. (Thu,) studied this question.